Period1 Oct 2023

Media coverage

1

Media coverage

  • TitleFDA Approves First-of-its-Kind Subcutaneous Infliximab Biosimilar
    Media name/outletDrug Topics (MJH)
    Country/TerritoryUnited States
    Date1/10/23
    PersonsJean-Frédéric Colombel